Exciting developments in healthcare are reshaping the landscape, bringing hope and innovation to the forefront. From groundbreaking gene therapies to advancements in AI-driven diagnostics, the pace of progress is remarkable. These strides not only improve patient care but also inspire collaboration and creativity across the industry. Let's embrace these advancements and continue driving positive change in healthcare together! #HealthcareInnovation #MedicalAdvances #RoboticTransplants
Dr. Aagam Shah’s Post
More Relevant Posts
-
The commercialization of cell and gene therapies (CGTs) is no easy task. With the FDA approving 7 new CGTs in 2023 alone, the total has risen to 34. But from high costs to healthcare infrastructure challenges, there’s a lot to navigate. Read more in this blog from Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, about how AI and innovative strategies are shaping the CGT landscape.
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time? In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk #CellGeneTherapy #CGT #PharmaInnovation #LifeSciences #EnvisionPharmaGroup
-
-
Executive - Life Sciences, Business and Organisation Strategy, Corporate Development, Business Development
The rapid evolution of cell and gene therapies (CGTs) has been incredible, with the FDA approving seven new therapies in 2023 alone. This growth is encouraging, but we still have hurdles to overcome, from ensuring healthcare systems are prepared to handle these complex treatments to addressing high costs. One trend catching my attention, which I was happy to write about in-depth with Kyle Felmet, is the shift toward rare diseases and autoimmune conditions fuelled by advancements in gene-editing technologies. These innovations, combined with AI's potential to navigate complex processes, optimise manufacturing and enhance patient outcomes, offer new avenues for more effective treatments and value-based pricing models. Like any life science innovation, we must remain focused on driving patient access and affordability while equipping healthcare systems to deliver these groundbreaking CGTs.
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time? In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk #CellGeneTherapy #CGT #PharmaInnovation #LifeSciences #EnvisionPharmaGroup
-
-
The journey to commercializing Cell and Gene Therapies (CGTs) is complex, but crucial advancements are being made. In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer at Envision Pharma Group, explore key trends reshaping the CGT landscape, from the growing focus on rare diseases to the impact of AI in optimizing costs and patient care. Discover what it takes to navigate the commercialization challenges in this rapidly evolving field. Read their blog below!
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time? In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk #CellGeneTherapy #CGT #PharmaInnovation #LifeSciences #EnvisionPharmaGroup
-
-
The commercialization of cell and gene therapies (CGTs) is no easy task. With the FDA approving 7 new CGTs in 2023 alone, the total has risen to 34. But from high costs to healthcare infrastructure challenges, there’s a lot to navigate. Read more in this blog from Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, about how AI and innovative strategies are shaping the CGT landscape.
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time? In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk #CellGeneTherapy #CGT #PharmaInnovation #LifeSciences #EnvisionPharmaGroup
-
-
The commercialization of cell and gene therapies (CGTs) is no easy task. With the FDA approving 7 new CGTs in 2023 alone, the total has risen to 34. But from high costs to healthcare infrastructure challenges, there’s a lot to navigate. Read more in this blog from Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, about how AI and innovative strategies are shaping the CGT landscape.
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time? In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk #CellGeneTherapy #CGT #PharmaInnovation #LifeSciences #EnvisionPharmaGroup
-
-
The commercialization of cell and gene therapies (CGTs) is no easy task. With the FDA approving 7 new CGTs in 2023 alone, the total has risen to 34. But from high costs to healthcare infrastructure challenges, there’s a lot to navigate. Read more in this blog from Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, about how AI and innovative strategies are shaping the CGT landscape.
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time? In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk #CellGeneTherapy #CGT #PharmaInnovation #LifeSciences #EnvisionPharmaGroup
-
-
The advent of cell and gene therapies is a promising shift in the healthcare landscape, yet it isn't without its unique challenges. From intricate manufacturing phases to regulatory complexities, these obstacles must be navigated for its full potential to be realized. In a recent interview with Clinical Leader, Roger Palframan, Head of US Research UCB, explores these issues - offering insight into how we can overcome them. Read it now: https://lnkd.in/dVvGxRE7 #CellAndGeneTherapy #HealthcareInnovation
-
-
The future of healthcare is on the horizon, and cell and gene therapies are poised to play a transformative role. But the question remains: when will this exciting potential become a reality for patients? To explore this critical topic, industry leaders and healthcare stakeholders are gathering today and tomorrow (April 15th-16th) at the 2nd Cell and Gene Therapy Summit, organised by The Economist. James Rutley, Autolomous Head of Business Development, is attending the summit and is eager to discuss the challenges of introducing advanced therapies into the mainstream and how we can tackle them together. We are committed to collaborating with fellow leaders to accelerate advancements in the CGT industry. Our ultimate goal? Ensuring broader patient access to these life-saving therapies. #networking #CellandGeneTherapy #PatientAccess
-
-
Read my White Paper on a Robust Chain of Custody in CGT ahead of #MeetingontheMesa. Learn more about CTI Clinical Trial and Consulting Services and how our expertise in #CGT can better support you!
The global #Cell & #GeneTherapy (CGT) market is expected to grow nearly 20% annually over the next decade, driven by breakthroughs in treating rare, once-incurable diseases. However, their personalized nature introduces unique logistical challenges, particularly in maintaining a robust chain of custody (CoC). Our latest white paper, "Ensuring a Robust Chain of Custody in Cell & Gene Therapies,” explores #CoC's crucial role in preserving #CGT integrity & efficacy, offering actionable insights & best practices for stakeholders. Read the full #WhitePaper here: https://bit.ly/3zmyzeu #MovingMedicineForward: CTI is excited to discuss the importance of CoC in CGT at the upcoming Alliance for Regenerative Medicine 2024 Cell & Gene Meeting on the Mesa, October 7-9 in Phoenix, AZ.
-
-
Embark on a Decade of Breakthroughs with DS InPharmatics! 🚀 Over the past ten years, the approval of cell and gene therapies has paved the way for extraordinary health outcomes for patients. 🌐💊 Curious about the FDA's role in guiding companies through the CMC requirements process for these groundbreaking therapies? 🧬🛠️ Dive into the details and elevate your understanding: https://bit.ly/3Hk9elP Stay informed, stay inspired! Let DS InPharmatics be your guide to the future of healthcare. 💙 #DSIGeneTherapies #HealthcareInnovation #FDAApprovals
-